Clinical trial

Single-center, Open-label, Multi-dose Study to Investigate the Human Mass Balance in Healthy Adult Male Following Multiple Oral Doses of HMPL-523 Tablets Followed by a Single Oral Dose of 300 mg/150 µCi [14C]HMPL-523 Suspension

Name
2022-523-00CH3
Description
To evaluate the absorption, metabolism and excretion of HMPL-523 in healthy male Chinese subjects following multiple oral doses of HMPL-523 tablets followed by a single oral dose of \[14C\]HMPL-523 suspension
Trial arms
Trial start
2023-02-08
Estimated PCD
2023-06-01
Trial end
2023-12-01
Status
Active (not recruiting)
Phase
Early phase I
Treatment
HMPL-523
D1-D7: HMPL-523 Tablet 300 mg QD
Arms:
HMPL-523
Other names:
HMPL-523 tablets
150 µCi [14C]HMPL-523
D8: \[14C\] HMPL-523 Suspension 300 mg/150 μCi Single dose
Arms:
HMPL-523
Other names:
150 µCi [14C]HMPL-523 suspension under fed condition
Size
10
Primary endpoint
the Human Mass Balance
Day1-Day7
the Human Mass Balance
Day8
Eligibility criteria
Inclusion Criteria: 1. Subjects who have voluntarily participated in the study and signed the informed consent form with good compliance; 2. Healthy male subjects aged 18-40 years (inclusive); 3. Subjects weighing ≥ 50 kg 4. Subjects in good health status Exclusion Criteria: 1. Subjects with a history of gastrointestinal surgery, renal surgery, cholecystectomy and other procedures that in the judgment of the investigator may affect drug absorption or excretion 2. hypersensitivity to the investigational product and its excipients 3. Subjects with diseases affecting the absorption, distribution, metabolism and excretion of oral drugs, 4. Subjects with fear of needles, hemophobia, difficulty collecting venous blood, or special requirements for diet, who cannot comply with uniform diet 5. Subjects who are abnormal with clinical significance for C-reactive protein or positive for coronavirus nucleic acid detection in coronavirus infection screening 6. Subjects who have participated in another clinical trial of other drugs and have received such investigational product within 3 months prior to the first dose 7. Having any other diseases or conditions that may affect the normal performance of the study or the evaluation of the study data, or having other conditions that are not suitable for the study, as judged by investigators
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SEQUENTIAL', 'primaryPurpose': 'HEALTH_SERVICES_RESEARCH', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 10, 'type': 'ESTIMATED'}}
Updated at
2023-07-11

1 organization

1 product

1 indication

Product
HMPL-523